The importance of recognizing and managing a rare form of angioedema: hereditary angioedema due to C1-inhibitor deficiency

References

• Maurer M, Magerl M, Ansotegui I, et al. The international WAO/EAACI guideline for the management of hereditary angioedema—The 2017 revision and update. Allergy. 2018;73(8):1575–1596.
   PubMed Web of Science ®Google Scholar
• Cicardi M, Bergamaschini B, Marasini B, et al. Hereditary angioedema: an appraisal of 104 cases. Am J Med Sci. 1982;284(1):2–9.
   PubMed Web of Science ®Google Scholar
• Bork K, Meng G, Staubach P, et al. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med. 2006;119(3):267–274.
   Web of Science ®Google Scholar
• Lumry W, Templeton T, Omert L, et al. Advances in hereditary angioedema: the prevention of angioedema attacks with subcutaneous C1-inhibitor replacement therapy. J Infus Nurs. 2020;43(3):134–145.
   PubMed Web of Science ®Google Scholar
• Bernstein JA, Cremonesi P, Hoffmann TK, et al. Angioedema in the emergency department: a practical guide to differential diagnosis and management. Int J Emerg Med. 2017;10(1):15.
   PubMedGoogle Scholar
• Long BJ, Koyfman A, Gottlieb M. Evaluation and management of angioedema in the emergency department. West J Emerg Med. 2019;20(4):587–600.
   PubMed Web of Science ®Google Scholar
• Bova M, De Feo G, Parente R, et al. Hereditary and acquired angioedema: heterogeneity of pathogenesis and clinical phenotypes. Int Arch Allergy Immunol. 2018;175(3):126–135.
   PubMed Web of Science ®Google Scholar
• Nzeako UC. Diagnosis and management of angioedema with abdominal involvement: a gastroenterology perspective. World J Gastroenterol. 2010;16(39): 4913–4921.
   PubMed Web of Science ®Google Scholar
• Moellman JJ, Bernstein JA, Lindsell C, et al. A consensus parameter for the evaluation and management of angioedema in the emergency department. Acad Emerg Med. 2014;21(4):469–484.
   PubMed Web of Science ®Google Scholar
• Lenschow M, Bas M, Johnson F, et al. A score for the differential diagnosis of bradykinin- and histamine-induced head and neck swellings. Eur Arch Otorhinolaryngol. 2018;275(7):1767–1773.
   PubMed Web of Science ®Google Scholar
• Aygören-Pürsün E, Magerl M, Maetzel A, et al. Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies. Orphanet J Rare Dis. 2018;13(1):73.
   PubMedGoogle Scholar
• Henao MP, Kraschnewski JL, Kelbel T, et al. Diagnosis and screening of patients with hereditary angioedema in primary care. Ther Clin Risk Manag. 2016;12:701–711.
   PubMed Web of Science ®Google Scholar
• Nzeako UC, Frigas E, Tremaine WJ. Hereditary angioedema: a broad review for clinicians. Arch Intern Med. 2001;161(20):2417–2429.
   Google Scholar
• Zanichelli A, Longhurst HJ, Maurer M, et al. Misdiagnosis trends in patients with hereditary angioedema from the real-world clinical setting. Ann Allergy Asthma Immunol. 2016;117(4):394–398.
   PubMed Web of Science ®Google Scholar
• Bernstein JA. HAE update: epidemiology and burden of disease. Allergy Asthma Proc. 2013;34(1):3–6.
   Web of Science ®Google Scholar
• Cicardi M, Agostoni A. Hereditary angioedema. N Engl J Med. 1996;334(25):1666–1667.
   Web of Science ®Google Scholar
• Cicardi M, Aberer W, Banerji A, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy. 2014;69(5):602–616.
   Google Scholar
• Bork K. Pasteurized and nanofiltered, plasma-derived C1 esterase inhibitor concentrate for the treatment of hereditary angioedema. Immunotherapy. 2014;6(5):533–551.
   Web of Science ®Google Scholar
• Agostoni A, Aygören-Pürsün E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol. 2004;114(3 Suppl):S51–S131.
   PubMed Web of Science ®Google Scholar
• Bork K, Gul D, Hardt J, et al. Hereditary angioedema with normal C1 inhibitor: clinical symptoms and course. Am J Med. 2007;120(11):987–992.
   Web of Science ®Google Scholar
• Bork K, Wulff K, Meinke P, et al. A novel mutation in the coagulation factor 12 gene in subjects with hereditary angioedema and normal C1-inhibitor. Clin Immunol. 2011;141(1):31–35.
   PubMed Web of Science ®Google Scholar
• Bova M, Suffritti C, Bafunno V, et al. Impaired control of the contact system in hereditary angioedema with normal C1-inhibitor. Allergy. 2020;75(6):1394–1403.
   PubMed Web of Science ®Google Scholar
• Bafunno V, Firinu D, D’Apolito M, et al. Mutation of the angiopoietin-1 gene (ANGPT1) associates with a new type of hereditary angioedema. J Allergy Clin Immunol. 2018;141(3):1009–1017.
   PubMed Web of Science ®Google Scholar
• Bork K, Wulff K, Rossmann H, et al. Hereditary angioedema cosegregating with a novel kininogen 1 gene mutation changing the N-terminal cleavage site of bradykinin. Allergy. 2019;74(12):2479–2481.
   PubMed Web of Science ®Google Scholar
• Bork K, Wulff K, Steinmüller-Magin L, et al. Hereditary angioedema with a mutation in the plasminogen gene. Allergy. 2018;73(2):442–450.
   PubMed Web of Science ®Google Scholar
• Ariano A, D’Apolito M, Bova M, et al. A myoferlin gain-of-function variant associates with a new type of hereditary angioedema. Allergy. 2020;75(11):2989–2992.
   PubMed Web of Science ®Google Scholar
• Bork K, Wulff K, Möhl BS, et al. Novel hereditary angioedema linked with a heparan sulfate 3-O-sulfotransferase 6 gene mutation. J Allergy Clin Immunol. 2021;S0091-6749(21)00094-4.
   PubMedGoogle Scholar
• Kaplan AP, Joseph K. Complement, kinins, and hereditary angioedema: mechanisms of plasma instability when C1 inhibitor is absent. Clin Rev Allergy Immunol. 2016;51(2):207–215.
   PubMed Web of Science ®Google Scholar
• Zuraw BL, Christiansen SC. HAE pathophysiology and underlying mechanisms. Clin Rev Allergy Immunol. 2016;51(2):216–229.
   PubMed Web of Science ®Google Scholar
• Longhurst HJ, Bork K. Hereditary angioedema: an update on causes, manifestations and treatment. Br J Hosp Med (Lond). 2019;80(7):391–398.
   PubMed Web of Science ®Google Scholar
• Germenis AE, Speletas M. Genetics of hereditary angioedema revisited. Clin Rev Allergy Immunol. 2016;51(2):170–182.
   Web of Science ®Google Scholar
• Kelemen Z, Moldovan D, Mihaly E, et al. Baseline level of functional C1-inhibitor correlates with disease severity scores in hereditary angioedema. Clin Immunol. 2010;134(3):354–358.
   PubMedGoogle Scholar
• Bafunno V, Bova M, Loffredo S, et al. Mutational spectrum of the c1 inhibitor gene in a cohort of Italian patients with hereditary angioedema: description of nine novel mutations. Ann Hum Genet. 2014;78(2):73–82.
   PubMed Web of Science ®Google Scholar
• Bork K, Staubach P, Eckardt AJ, et al. Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 inhibitor deficiency. Am J Gastroenterol. 2006;101(3):619–627.
   PubMed Web of Science ®Google Scholar
• Testori A, Melamed I. Neurological manifestations of hereditary angioedema. Ann Allergy Asthma Immunol. 2017;118(1):119–120.
   PubMed Web of Science ®Google Scholar
• Bonnaud I, Rouaud V, Guyot M, et al. Exceptional stroke-like episodes in a patient with type 1 autosomal angioedema. Neurology. 2012;78(8):598.
   PubMed Web of Science ®Google Scholar
• Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol. 2012;130(3):692–697.
   PubMed Web of Science ®Google Scholar
• Bork K, Brehler R, Witzke G, et al. Blindness, tetraspasticity, and other signs of irreversible brain damage in hereditary angioedema. Ann Allergy Asthma Immunol. 2017;118(4):520–521.
   PubMed Web of Science ®Google Scholar
• Banerji A. The burden of illness in patients with hereditary angioedema. Ann Allergy Asthma Immunol. 2013;111(5):329–336.
   PubMedGoogle Scholar
• Lumry WR, Castaldo AJ, Vernon MK, et al. The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc. 2010;31(5):407–414.
   PubMed Web of Science ®Google Scholar
• Busse PJ, Christiansen SC. Hereditary angioedema. N Engl J Med. 2020;382(12):1136–1148.
   PubMedGoogle Scholar
• Zuraw BL, Christiansen SC. How we manage persons with hereditary angioedema. Br J Haematol. 2016;173(6):831–843.
   PubMed Web of Science ®Google Scholar
• Caballero T, Maurer M, Longhurst HJ, et al. Triggers and prodromal symptoms of angioedema attacks in patients with hereditary angioedema. J Investig Allergol Clin Immunol. 2016;26(6):283–386.
   Web of Science ®Google Scholar
• Banerji A, Busse P, Christiansen SC, et al. Current state of hereditary angioedema management: a patient survey. Allergy Asthma Proc. 2015;36(3):213–217.
   PubMed Web of Science ®Google Scholar
• Aygören-Pürsün E, Bygum A, Beusterien K, et al. Estimation of EuroQol 5-dimensions health status utility values in hereditary angioedema. Patient Prefer Adherence. 2016;10:1699–1707.
   PubMed Web of Science ®Google Scholar
• Jindal NL, Harniman E, Prior N, et al. Hereditary angioedema: health-related quality of life in Canadian patients as measured by the SF-36. Allergy Asthma Clin Immunol. 2017;13:4.
   PubMed Web of Science ®Google Scholar
• Kuman Tunçel Ö, Gökmen NM, Demir E, et al. The impact of hereditary angioedema on quality of life and family planning decisions. Int J Psychiatry Med. 2019;54(6):377–394.
   PubMed Web of Science ®Google Scholar
• Caballero T, Aygören-Pürsün E, Bygum A, et al. The humanistic burden of hereditary angioedema: results from the Burden of Illness Study in Europe. Allergy Asthma Proc. 2014;35(1):47–53.
   PubMed Web of Science ®Google Scholar
• Fouche AS, Saunders EF, Craig T. Depression and anxiety in patients with hereditary angioedema. Ann Allergy Asthma Immunol. 2014;112(4):371–375.
   PubMed Web of Science ®Google Scholar
• Kessel A, Farkas H, Kivity S, et al. The relationship between anxiety and quality of life in children with hereditary angioedema. Pediatr Allergy Immunol. 2017;28(7):692–698.
   PubMed Web of Science ®Google Scholar
• Nordenfelt P, Dawson S, Wahlgren CF, et al. Quantifying the burden of disease and perceived health state in patients with hereditary angioedema in Sweden. Allergy Asthma Proc. 2014;35(2):185–190.
   PubMed Web of Science ®Google Scholar
• Wilson DA, Bork K, Shea EP, et al. Economic costs associated with acute attacks and long-term management of hereditary angioedema. Ann Allergy Asthma Immunol. 2010;104(4):314–320.
   PubMed Web of Science ®Google Scholar
• Aygören-Pürsün E, Bygum A, Beusterien K, et al. Socioeconomic burden of hereditary angioedema: results from the hereditary angioedema burden of illness study in Europe. Orphanet J Rare Dis. 2014;9:99.
   PubMed Web of Science ®Google Scholar
• Lumry WR, Craig T, Zuraw B, et al. Health-related quality of life with subcutaneous C1-inhibitor for prevention of attacks of hereditary angioedema. J Allergy Clin Immunol Pract. 2018;6(5):1733–1741.e3.
   PubMed Web of Science ®Google Scholar
• Zanichelli A, Magerl M, Longhurst H, et al. Hereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe. Allergy Asthma Clin Immunol. 2013;9(1):29.
   PubMed Web of Science ®Google Scholar
• Bygum A. Hereditary angio-oedema in Denmark: a nationwide survey. Br J Dermatol. 2009;161(5):1153–1158.
   PubMed Web of Science ®Google Scholar
• Frank MM, Zuraw B, Banerji A, et al. Management of children with hereditary angioedema due to C1 inhibitor deficiency. Pediatrics. 2016;138(5).
   Web of Science ®Google Scholar
• Farkas H. Pediatric hereditary angioedema due to C1-inhibitor deficiency. Allergy Asthma Clin Immunol. 2010;6(1):18.
   PubMedGoogle Scholar
• Berger J, Carroll MP, Champoux E, et al. Extremely delayed diagnosis of type II hereditary angioedema: case report and review of the literature. Mil Med. 2018;183(11–12):e765–e767.
   PubMed Web of Science ®Google Scholar
• Hahn J, Hoess A, Friedrich DT, et al. Unnecessary abdominal interventions in patients with hereditary angioedema. J Dtsch Dermatol Ges. 2018;16(12):1443–1449.
   Web of Science ®Google Scholar
• Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA medical advisory board 2020 guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2021;9:132–150.
   PubMed Web of Science ®Google Scholar
• Farkas H, Martinez-Saguer I, Bork K, et al. International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency. Allergy. 2017;72(2):300—313.
   Google Scholar
• Abdel-Samad NN, Kokai JS. A case of acquired angioedema with low C1 inhibitor (C1-INH) associated with splenic marginal zone lymphoma. Am J Case Rep. 2019;20:1476–1481.
   PubMed Web of Science ®Google Scholar
• Bork K, Machnig T, Wulff K, et al. Clinical features of genetically characterized types of hereditary angioedema with normal C1 inhibitor: a systematic review of qualitative evidence. Orphanet J Rare Dis. 2020;15(1):289.
   PubMed Web of Science ®Google Scholar
• Li HH, Busse P, Lumry WR, et al. Comparison of chromogenic and ELISA functional C1 inhibitor tests in diagnosing hereditary angioedema. J Allergy Clin Immunol Pract. 2015;3(2):200–205.
   PubMed Web of Science ®Google Scholar
• Cicardi M, Zuraw BL. Angioedema due to bradykinin dysregulation. J Allergy Clin Immunol Pract. 2018;6(4):1132–1141.
   PubMed Web of Science ®Google Scholar
• Gower RG. HAE update: determining optimal patient specific therapy. Allergy Asthma Proc. 2013;34(1):7–12.
   PubMed Web of Science ®Google Scholar
• Bork K. A decade of change: recent developments in pharmacotherapy of hereditary angioedema (HAE). Clin Rev Allergy Immunol. 2016;51(2):183–192.
   PubMed Web of Science ®Google Scholar
• Cicardi M, Bork K, Caballero T, et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy. 2012;66(2):147–157.
   PubMed Web of Science ®Google Scholar
• Craig TJ, Aygören-Pürsün E, Bork K, et al. WAO guideline for the management of hereditary angioedema. World Allergy Organ J. 2012;5(12):182–199.
   PubMedGoogle Scholar
• Lang DM, Aberer W, Bernstein JA, et al. International consensus on hereditary and acquired angioedema. Ann Allergy Asthma Immunol. 2012;109:395–402.
   PubMed Web of Science ®Google Scholar
• Wahn V, Aberer W, Eberl W, et al. Hereditary angioedema (HAE) in children and adolescents—a consensus on therapeutic strategies. Eur J Pediatr. 2012;171:1339–1348.
   PubMed Web of Science ®Google Scholar
• Zuraw BL, Banerji A, Bernstein JA, et al. US hereditary angioedema association medical advisory board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency. J Allergy Clin Immunol Pract. 2013;1(5):458–467.
   PubMed Web of Science ®Google Scholar
• Betschel S, Badiou J, Binkley K, et al. Canadian hereditary angioedema guideline. Allergy Asthma Clin Immunol. 2014;10:50.
   PubMed Web of Science ®Google Scholar
• Craig T, Riedl M, Dykewicz MS, et al. When is prophylaxis for hereditary angioedema necessary? Ann Allergy Asthma Immunol. 2009;102(5):366–372.
   PubMed Web of Science ®Google Scholar
• Longhurst H, Zinser E. Prophylactic therapy for hereditary angioedema. Immunol Allergy Clin North Am. 2017;37(3):557–570.
   PubMed Web of Science ®Google Scholar
• Bygum A, Andersen KE, Mikkelsen CS. Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits. Eur J Dermatol. 2009;19(2):147–151.
   PubMed Web of Science ®Google Scholar
• Longhurst HJ, Farkas H, Craig T, et al. HAE international home therapy consensus document. Allergy Asthma Clin Immunol. 2010;6(1):22.
   PubMedGoogle Scholar
• Boysen HB, Bouillet L, Aygören-Pürsün E. Challenges of C1-inhibitor concentrate self-administration. Int Arch Allergy Immunol. 2013;161 Suppl 1:21–25.
   PubMed Web of Science ®Google Scholar
• Cicardi M, Craig TJ, Martinez-Saguer I, et al. Review of recent guidelines and consensus statements on hereditary angioedema therapy with focus on self-administration. Int Arch Allergy Immunol. 2013;161 Suppl 1:3–9.
   PubMed Web of Science ®Google Scholar
• Li HH. Self-administered C1 esterase inhibitor concentrates for the management of hereditary angioedema: usability and patient acceptance. Patient Prefer Adherence. 2016;10:1727–1737.
   PubMed Web of Science ®Google Scholar
• Gregory C, Landmesser LM, Corrigan L, et al. Feasibility of home infusion and self-administration of nanofiltered C1 esterase inhibitor for routine prophylaxis in patients with hereditary angioedema and characterization of a training and support program. J Infus Nurs. 2014;37(1):29–34.
   PubMedGoogle Scholar
• Farkas H, Martinez-Saguer I, Bork K, et al. International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency. Allergy. 2017;72(2):300–313.
   PubMed Web of Science ®Google Scholar
• Gower RG, Lumry WR, Davis-Lorton MA, et al. Current options for prophylactic treatment of hereditary angioedema in the United States: patient-based considerations. Allergy Asthma Proc. 2012;33(3):235–240.
   PubMed Web of Science ®Google Scholar
• Zuraw BL, Davis DK, Castaldo AJ. Tolerability and effectiveness of 17-α-alkylated androgen therapy for hereditary angioedema: a re-examination. J Allergy Clin Immunol Pract. 2016;4(5):948–955.e15.
   PubMed Web of Science ®Google Scholar
• Tse KY, Zuraw BL, Chen Q, et al. Anabolic androgen use in the management of hereditary angioedema: not so cheap after all. Ann Allergy Asthma Immunol. 2017;118(4):456–460.e1.
   PubMed Web of Science ®Google Scholar
• BERINERT® [package insert]. Kankakee, IL: CSL Behring, LLC; 2019.
   Google Scholar
• RUCONEST® [package insert]. Warren, NJ: Pharming Healthcare Inc.; 2020.
   Google Scholar
• FIRAZYR® [package insert]. Lexington, MA: Shire Orphan Therapies LLC, now part of Takeda; 2015.
   Google Scholar
• KALBITOR® [package insert]. Burlington, MA: Dyax Corp, now part of Takeda; 2015.
   Google Scholar
• DANOCRINE® prescribing information. Bridgewater, NJ: Sanofi-Aventis US LLC. December 2011.
   Google Scholar
• CINRYZE® [package insert]. Lexington, MA: ViroPharma Biologics LLC, a Takeda Company; 2021.
   Google Scholar
• HAEGARDA® [package insert]. Kankakee, IL: CSL Behring, LLC; 2017.
   Google Scholar
• TAKHZYRO^TM [package insert]. Lexington, MA: Dyax Corp, now part of Takeda; 2018.
   Google Scholar
• ORLADEYO^TM [package insert]. Durham, NC: BioCryst Pharmaceuticals, Inc.; 2020.
   Google Scholar
• Brackertz D, Kueppers F. Hereditary angioneurotic oedema. Lancet. 1973;2(7830):680.
   PubMed Web of Science ®Google Scholar
• Riedl MA, Grivcheva-Panovska V, Moldovan D, et al. Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial. Lancet. 2017;390(10102):1595–1602.
   PubMed Web of Science ®Google Scholar
• Riedl MA, Banerji A, Busse PJ, et al. Patient satisfaction and experience with intravenously administered C1-inhibitor concentrates in the United States. Ann Allergy Asthma Immunol. 2017;119(1):59–64.
   PubMed Web of Science ®Google Scholar
• Zuraw BL, Kalfus I. Safety and efficacy of prophylactic nanofltered C1-inhibitor in hereditary angioedema. Am J Med. 2012;125(9):938.e1–7.
   PubMed Web of Science ®Google Scholar
• Yoo SM, Khan DA. Implantable venous access device associated complications in patients with hereditary angioedema. J Allergy Clin Immunol Pract. 2013;1(5):524–525.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA approves first subcutaneous C1 Esterase Inhibitor to treat rare genetic disease. 2017 Jun [cited 2020 Feb 7]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-subcutaneous-c1-esterase-inhibitor-treat-rare-genetic-disease.
   Google Scholar
• Zuraw BL, Cicardi M, Longhurst HJ, et al. Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1-inhibitor concentrate. Allergy. 2015;70(10):1319–1328.
   PubMed Web of Science ®Google Scholar
• Longhurst H, Cicardi M, Craig T, et al. COMPACT Investigators. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. N Engl J Med. 2017;376(12):1131–1140.
   PubMed Web of Science ®Google Scholar
• Craig T, Zuraw B, Longhurst H, et al. for the COMPACT Investigators. Long-term outcomes with subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. J Allergy Clin Immunol Pract. 2019;7(6):1793–1802.
   PubMed Web of Science ®Google Scholar
• Craig T, Lumry W, Cicardi M, et al. Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings. J Allergy Clin Immunol Pract. 2019;7(6):2035–2038.
   PubMed Web of Science ®Google Scholar
• Banerji A, Busse P, Shennak M, et al. Inhibiting plasma kallikrein for hereditary angioedema prophylaxis. N Engl J Med. 2017;376(8):717–728.
   PubMed Web of Science ®Google Scholar
• Banerji A, Riedl MA, Bernstein JA, et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA. 2018;320(20):2108–2121. 10.1001/jama.2018.16773. Erratum in: JAMA. 2019 Apr 23;321(16):1636.
   Google Scholar
• Riedl MA, Maurer M, Bernstein JA, et al. HELP Investigators. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. Allergy. 2020;75(11):2879–2887.
   PubMed Web of Science ®Google Scholar
• Riedl MA, Bernstein JA, Craig T, et al. An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension. Clin Transl Allergy. 2017;7:36.
   PubMed Web of Science ®Google Scholar
• Banerji A, Hao J, Yu M, et al. Long-term efficacy and safety of lanadelumab: final results from the HELP open-label extension study [abstract P150]. Allergy Asthma Immunol. 2020;125:S21.
   Web of Science ®Google Scholar
• Zuraw B, Lumry WR, Johnston DT, et al. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial. J Allergy Clin Immunol. 2020;S0091-6749(20):31484–31486.
   Google Scholar
• Valerieva A, Staevska M, Jesenak M, et al. Recominant huima C1 esterase as short-term prophylaxis in patients with hereditary angioedema. J Allergy Clin Immunol Pract. 2020;8(2):799–802.
   PubMed Web of Science ®Google Scholar
• Martinez-Saguer I, Rusicke E, Aygören-Pürsün E, et al. Characterization of acute hereditary angioedema attacks during pregnancy and breast-feeding and their treatment with C1 inhibitor concentrate. Am J Obstet Gynecol. 2010;203(2):131.e1–7.
   PubMed Web of Science ®Google Scholar
• Bouillet L, Longhurst H, Boccon-Gibod I, et al. Disease expression in women with hereditary angioedema. Am J Obstet Gynecol. 2008;199(5):484.e1–484.e4.
   PubMed Web of Science ®Google Scholar
• Fox J, Vegh AB, Martinez-Saguer I, et al. Safety of a C1-inhibitor concentrate in pregnancy women with hereditary angioedema. Allergy Asthma Proc. 2017;38(3):216–221.
   PubMedGoogle Scholar
• Levy DS, Farkas H, Riedl MA, et al. Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial. Allergy Asthma Clin Immunol. 2020;16:8.
   PubMed Web of Science ®Google Scholar
• Caballero T, Canabal J, Rivero-Paparoni D, et al. Management of hereditary angioedema in pregnant women: a review. Int J Women’s Health. 2014;6:839–848.
   PubMedGoogle Scholar
• Bork K, Hardt J, Schicketanz KH, et al. Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Arch Intern Med. 2003;163(10):1229–1235.
   PubMedGoogle Scholar
• CSL Behring. CSL312 (Garadacimab) in the prevention of hereditary angioedema attacks. [ cited 2021 Mar 3]. Available from: https://clinicaltrials.gov/ct2/show/NCT04656418?term=Garadacimab&draw=2&rank=1.
   Google Scholar
• Ionis Pharmaceuticals Inc. A study to assess the clinical efficacy of IONIS-PKK-LRx in participants with hereditary angioedema. [ cited 2021 Mar 3]. Available from: https://clinicaltrials.gov/ct2/show/NCT04030598?term=ionis-pkk&draw=2&rank=3.
   Google Scholar
• Ionis Pharmaceuticals Inc. An extension study of IONIS-PKK-LRx in participants with hereditary angioedema. [ cited 2021 Mar 3]. Available from: https://clinicaltrials.gov/ct2/show/NCT04307381?term=Ionis-PKK&draw=2&rank=2.
   Google Scholar
• Pharvaris Netherlands B.V. Dose-ranging study of oral PHA-022121 for acute treatment of angioedema attacks in patients with hereditary angioedema (RAPIDe-1). [ cited 2021 Mar 3]. Available from: https://clinicaltrials.gov/ct2/show/NCT04618211?term=PHA121&draw=2&rank=1.
   Google Scholar
• KalVista Pharmaceuticals. A phase II, cross-over clinical trial evaluating the efficacy and safety of KVD900 in the on-demand treatment of angioedema attacks in adult subjects with hereditary angioedema Type I or II. [ cited 2021 Mar 3]. Available from: https://clinicaltrials.gov/ct2/show/NCT04208412?term=KVD900&draw=2&rank=1.
   Google Scholar
• KalVista Pharmaceuticals. KVD824 for HAE. [ cited 2021 Mar 9]. Available from: https://www.kalvista.com/products-pipeline/kvd824-hae.
   Google Scholar